{"entity":{"id":"nct04457596","kind":"trial","name":"CompassHER2 RD","aka":["T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial"],"tldr":"CompassHER2 RD compares T-DM1 with or without tucatinib after surgery when cancer remains following pre-surgery therapy. It asks whether adding tucatinib lowers the chance of relapse.","summary":"CompassHER2 RD compares T-DM1 with or without tucatinib after surgery when cancer remains following pre-surgery therapy. It asks whether adding tucatinib lowers the chance of relapse.\n\nInterventional study registered as NCT04457596, sponsored by Alliance for Clinical Trials in Oncology. Registry phase: 3. Registry enrollment is 1,056 participants (actual). Registry status checked October 10, 2026: active not recruiting. UCSF lists this study as closed to local enrollment; local availability and overall registry status are separate. See the registry for full eligibility and current sites.","status":"active","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT04457596","url":"https://clinicaltrials.gov/study/NCT04457596"},{"label":"UCSF study listing and local availability","url":"https://clinicaltrials.ucsf.edu/trial/NCT04457596"}],"tags":["ucsf-breast-coverage","interventional"],"related":[],"cancers":["breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-emtansine","tucatinib"],"companies":[],"institutions":["ucsf"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04457596","phase":"3","setting":"High-risk HER2-positive breast cancer with residual disease after pre-surgery treatment","sponsor":"Alliance for Clinical Trials in Oncology","participation":[{"nct":"NCT04457596","source":"https://clinicaltrials.gov/study/NCT04457596","fetchedAt":"2026-10-10T20:54:22.784557Z","studySha256":"f27612e78c43de7af89362cdaa3a691206a9c8de9ebbb937be29dd49fbe19088","overallStatus":"ACTIVE_NOT_RECRUITING","lastUpdatePosted":"2026-06-15","leadSponsor":"Alliance for Clinical Trials in Oncology","collaboratorCount":2,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":1056,"enrolmentType":"ACTUAL","siteCount":1176,"recruitingSiteCount":0,"countries":["Canada","Puerto Rico","United States"]}],"started":"2021-03-02","startedType":"actual","enrolled":1056,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04457596/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"}],"drug":[{"id":"trastuzumab-emtansine","kind":"drug","name":"Trastuzumab emtansine","route":"/drugs/trastuzumab-emtansine/"},{"id":"tucatinib","kind":"drug","name":"Tucatinib","route":"/drugs/tucatinib/"}],"institution":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/"}]}}